BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 25607647)

  • 1. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
    Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
    Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
    Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
    Mi W; Ye Q; Liu S; She QB
    Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
    Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
    Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Cancer Effect of Cap-Translation Inhibitor 4EGI-1 in Human Glioma U87 Cells: Involvement of Mitochondrial Dysfunction and ER Stress.
    Wu M; Zhang C; Li XJ; Liu Q; Wanggou S
    Cell Physiol Biochem; 2016; 40(5):1013-1028. PubMed ID: 27941351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
    J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation.
    George A; Panda S; Kudmulwar D; Chhatbar SP; Nayak SC; Krishnan HH
    J Biol Chem; 2012 Feb; 287(7):5042-58. PubMed ID: 22184107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth-factor dependent expression of the translationally controlled tumour protein TCTP is regulated through the PI3-K/Akt/mTORC1 signalling pathway.
    Bommer UA; Iadevaia V; Chen J; Knoch B; Engel M; Proud CG
    Cell Signal; 2015 Aug; 27(8):1557-68. PubMed ID: 25936523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPIP promotes gastric cancer cell proliferation through activation of cap-dependent translation.
    Chen B; Zhao J; Zhang S; Zhang Y; Huang Z
    Oncol Rep; 2016 Dec; 36(6):3664-3672. PubMed ID: 27748944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
    Misra UK; Pizzo SV
    PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling.
    Coffey RT; Shi Y; Long MJ; Marr MT; Hedstrom L
    J Biol Chem; 2016 Mar; 291(10):5221-33. PubMed ID: 26740621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
    Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
    Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
    Sathe A; Chalaud G; Oppolzer I; Wong KY; von Busch M; Schmid SC; Tong Z; Retz M; Gschwend JE; Schulz WA; Nawroth R
    PLoS One; 2018; 13(1):e0190854. PubMed ID: 29357370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
    De A; Jacobson BA; Peterson MS; Jay-Dixon J; Kratzke MG; Sadiq AA; Patel MR; Kratzke RA
    Invest New Drugs; 2018 Apr; 36(2):217-229. PubMed ID: 29116477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
    Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
    PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia.
    Schwarzer A; Holtmann H; Brugman M; Meyer J; Schauerte C; Zuber J; Steinemann D; Schlegelberger B; Li Z; Baum C
    Oncogene; 2015 Jul; 34(27):3593-604. PubMed ID: 25241901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.